According to data from the American Academy of Implant Dentistry, the annual dental implant market reaches $1.3 billion in the US, $8.1 billion globally, and the numbers are still growing. Despite significant progress in clinical success rates in recent years, an 8% implant failure rate translates into more than one million failed implants per year worldwide with infection being one of the most prevalent causes for implant failure. Indeed, 20% of implants with an average function time of 5 to 11 years develop periimplantitis, which demonstrates the severity of the problem. Functionalization of titanium surfaces with coatings made of antimicrobial agents has recently been explored to inhibit periimplant infections. The coatings can contain nanoparticles of pure elements ; sanitizing agents and disinfectants ; and antibiotics as well as antimicrobial peptides. Gentamicin and Vancomycin have been coated on Ti surfaces for protecting from infection dental and orthopedic implants. Although antibiotic coatings on titanium proved to be effective in vitro and in vivo, their use is controversial because of their potential host cytotoxicity and bacterial resistance. The use of antimicrobial peptides as an antimicrobial approach to improve implant performance has recently been introduced due to their broad-spectrum activity against bacteria, fungi and virus, low host cytotoxicity, and low bacterial resistance. Different cationic antimicrobial peptides derived from human proteins have been either physically adsorbed or covalently attached on implant surfaces. These implants displayed antimicrobial activity against pathogens related with orthopedic peri-implantitis. We have focused on developing an antimicrobial peptide coating with activity against pathogens associated with dental periimplantitis. In our previous work, we bonded the antimicrobial peptide GL13K to titanium surfaces using silane coupling agents to produce coatings that have covalent attachment to the metallic substrate and that have significant antimicrobial activity against the Gram negative bacterium Porphyromonas gingivalis, an oral pathogen that is closely associated with the development of biofilms and dental peri-implantitis. The peptide, GL13K, which was derived from the human salivary protein Parotid WY 14643 purchase Secretory Protein, exhibited an MIC of 8 mg/ml against planktonic Pseudonomas aeruginosa and their biofilms were reduced by three orders of magnitude with 100 mg/ml GL13K. This peptide concentration also killed 100% of Streptococcus gordonii. At 1 mg/ml, GL13K caused less than 10% lysis of human red blood cells, suggesting low toxicity to mammalian cells. The GL13K peptide coating showed bactericidal effect and inhibition of biofilm growth against peri-implantitis related pathogens, such as Porphyromonas gingivalis. Additionally, the coating had resistance to hydrolytic and mechanical challenges with no significant release of peptides from the titanium surface and was cytocompatible with osteoblasts and human gingival fibroblasts.